WHAT IS THE PURPOSE OF THE STUDY?


This research is being conducted to determine if an investigational medicine called IGNX001 has the potential to provide protection against accidental peanut exposure in patients with diagnosed history of peanut allergy. IGNX001 is an injectable antibody that targets peanut protein.

The study will monitor the safety of IGNX001, track how participants tolerate it, and explore whether participants improve their tolerance to peanut protein exposure by receiving IGNX001.



We are currently recruiting participants for a clinical research study to evaluate the safety and other properties of the allergen-specific antibody investigational medicine in treating adults and older adolescents with peanut allergy.





Learn how you or your older adolescent child could participate in a research study of IGNX001 which may ease allergic reactions that occur from accidental exposure to peanut.



The results of this study will provide more information about IGNX001 and whether it can help treat peanut allergy

WHAT ARE CLINICAL RESEARCH STUDIES?

Clinical research studies help scientists and doctors explore whether a medicine, device, or therapy is safe and effective to use in people. Before any investigational therapy can be approved and made available to the public, it must go through several phases of clinical research.

Study participation usually involves visiting a clinic regularly, receiving an investigational medicine, and undergoing tests and procedures to monitor your health. You can still see your regular doctor, but you should let them know you or your child are participating in a study.

WHO IS ELIGIBLE TO PARTICIPATE IN THIS STUDY?

To pre-qualify for this study, you or your adolescent child must:

- Be 15 to 55 years of age inclusive
- Have a history of peanut allergy and experienced a reaction to peanut within the last 15 years
- Be willing to avoid peanuts and other allergy inducing foods during the course of the study.

You or your adolescent child must NOT have:

- A history of severe or life-threatening anaphylaxis
- A history of severe or uncontrolled asthma within the last 6 months
- Any significant acute disease or uncontrolled chronic disease
- Received food allergen immunotherapy treatment or participated in a similar study in the past 12 months

WHAT WILL HAPPEN DURING THIS STUDY?

You or your adolescent child will need to visit the study center several times over a 6-month period.

The investigational medicine will be given in no more than 4 injections near the belly button or in the upper arm/thigh.

Several tests and assessments will be performed to monitor your health throughout the course of the study.

These assessments include:

- Collection of medical history
- Review prior & current medications
- Completion of physical exams
- Collection of blood & urine samples
- Electrocardiograms (ECG)
- Skin prick tests
- Peanut oral food challenges

WHAT ELSE SHOULD I KNOW?

While you or your adolescent child could benefit from participating in this study, that cannot be guaranteed. However, your participation may help people with peanut allergies in the future.

The sponsor of this study was required to design a protocol, which explains all study procedures in detail. An ethics committee responsible for participant safety reviewed this protocol and requires that it be followed exactly.

You may be compensated for your time and reimbursed for any reasonable out-of-pocket expenses including travel.

For more information about the study, please contact:

- Fiona Stanley Hospital (WA) <u>fshimmunology.research@health.wa.gov.au</u>
- St Vincent's Hospital (NSW) <u>PeanutAllergy@svha.org.au</u>
- The Royal Melbourne Hospital (VIC)
 respiratorymedicine.trials@monashhealth.org
- Monash Health (VIC) <u>AllergyResearch@mh.org.au</u>